Suivre
Christopher Montemagno
Christopher Montemagno
Chercheur post doctorant chez Centre Scientifique de Monaco
Adresse e-mail validée de centrescientifique.mc
Titre
Citée par
Citée par
Année
Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs
C Montemagno, G Pagès
Frontiers in Cell and Developmental Biology 8, 584, 2020
612020
LIM kinase inhibitor Pyr1 reduces the growth and metastatic load of breast cancers
C Prunier, V Josserand, J Vollaire, E Beerling, C Petropoulos, O Destaing, ...
Cancer Research 76 (12), 3541-3552, 2016
332016
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
C Montemagno, A Hagege, D Borchiellini, B Thamphya, O Rastoin, ...
Oncoimmunology 9 (1), 1846901, 2020
302020
Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy
D Ambrosetti, M Coutts, C Paoli, M Durand, D Borchiellini, C Montemagno, ...
BJU international 129 (1), 80-92, 2022
282022
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
C Montemagno, S Cassim, J Pouyssegur, A Broisat, G Pagès
International Journal of Molecular Sciences 21 (11), 4067, 2020
202020
Integrin-αvβ3 as a therapeutic target in glioblastoma: back to the future?
W Echavidre, V Picco, M Faraggi, C Montemagno
Pharmaceutics 14 (5), 1053, 2022
172022
Evaluation of antiatherogenic properties of ezetimibe using 3H-labeled low-density-lipoprotein cholesterol and 99mTc-cAbVCAM1–5 SPECT in ApoE−/− mice fed the Paigen diet
LS Dumas, F Briand, R Clerc, E Brousseau, C Montemagno, M Ahmadi, ...
Journal of Nuclear Medicine 58 (7), 1088-1093, 2017
162017
99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
C Montemagno, S Cassim, D Trichanh, C Savary, J Pouyssegur, G Pagès, ...
Cancers 11 (10), 1531, 2019
152019
Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
A Dumond, E Brachet, J Durivault, V Vial, AK Puszko, Y Lepelletier, ...
Journal of experimental & clinical cancer research 40, 1-18, 2021
142021
Preclinical evaluation of mesothelin-specific ligands for SPECT imaging of triple-negative breast cancer
C Montemagno, S Bacot, M Ahmadi, B Kerfelec, D Baty, M Debiossat, ...
Journal of Nuclear Medicine 59 (7), 1056-1062, 2018
142018
Pancreatic ductal adenocarcinoma: the dawn of the era of nuclear medicine?
C Montemagno, S Cassim, N De Leiris, J Durivault, M Faraggi, G Pagès
International Journal of Molecular Sciences 22 (12), 6413, 2021
132021
Anti-vascular endothelial growth factor C antibodies efficiently inhibit the growth of experimental clear cell renal cell carcinomas
A Dumond, C Montemagno, V Vial, R Grépin, G Pagès
Cells 10 (5), 1222, 2021
132021
In vivo biodistribution and efficacy evaluation of NeoB, a radiotracer targeted to GRPR, in mice bearing gastrointestinal stromal tumor
C Montemagno, F Raes, M Ahmadi, S Bacot, M Debiossat, J Leenhardt, ...
Cancers 13 (5), 1051, 2021
122021
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
A Hagege, E Saada-Bouzid, D Ambrosetti, O Rastoin, J Boyer, X He, ...
Cell Reports Medicine 3 (9), 2022
112022
Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical …
N de Leiris, J Leenhardt, B Boussat, C Montemagno, A Seiller, O Phan Sy, ...
Cancer Imaging 20, 1-11, 2020
102020
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
C Montemagno, G Pagès
Cancers 12 (4), 821, 2020
102020
Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody
M Nachit, C Montemagno, R Clerc, M Ahmadi, F Briand, S Bacot, ...
Nature Communications 14 (1), 1062, 2023
92023
Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
M Pagnuzzi-Boncompagni, V Picco, V Vial, V Planas-Bielsa, ...
Cancers 14 (1), 70, 2021
92021
In vivo assessment of VCAM-1 expression by SPECT/CT imaging in mice models of human triple negative breast cancer
C Montemagno, L Dumas, P Cavaillès, M Ahmadi, S Bacot, M Debiossat, ...
Cancers 11 (7), 1039, 2019
82019
Assessment of in vivo biodistribution and treatment efficacy of Lu-177 PSMA-R2 and Lu-177-PSMA-617 on mice bearing prostate cancer tumors
V Muzio, L Ravasi, L Sacchetti, L Fugazza, S Bacot, M Debiossat, ...
European journal of nuclear medicine and molecular imaging 46 (SUPPL 1), S17-S17, 2019
32019
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20